When initial therapy is ineffective in patients with
HABP/VABP or cSSSI due to S. aureus, choose VIBATIV.
The once-daily antibiotic infusion with a dual mechanism
of action indicated for MRSA and MSSA
Learn about VIBATIV for the treatment of hospital–acquired and ventilator–associated pneumonia, including MRSA and MSSA.
Learn about VIBATIV for the treatment of complicated skin and skin structure infections.